- Home
- VALU vs CRVS Comparison
VALU vs CRVS Comparison
Compare VALU & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- CRVS
- Stock Information
- Founded
- VALU 1931
- CRVS 2014
- Country
- VALU United States
- CRVS United States
- Employees
- VALU N/A
- CRVS N/A
- Industry
- VALU Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- CRVS Health Care
- Exchange
- VALU Nasdaq
- CRVS Nasdaq
- Market Cap
- VALU 530.8M
- CRVS 451.0M
- IPO Year
- VALU N/A
- CRVS 2016
- Fundamental
- Price
- VALU $54.40
- CRVS $8.19
- Analyst Decision
- VALU
- CRVS Buy
- Analyst Count
- VALU 0
- CRVS 4
- Target Price
- VALU N/A
- CRVS $12.83
- AVG Volume (30 Days)
- VALU 11.3K
- CRVS 1.1M
- Earning Date
- VALU 12-13-2024
- CRVS 11-12-2024
- Dividend Yield
- VALU 2.21%
- CRVS N/A
- EPS Growth
- VALU 8.76
- CRVS N/A
- EPS
- VALU 2.13
- CRVS N/A
- Revenue
- VALU $36,628,000.00
- CRVS N/A
- Revenue This Year
- VALU N/A
- CRVS N/A
- Revenue Next Year
- VALU N/A
- CRVS N/A
- P/E Ratio
- VALU $25.58
- CRVS N/A
- Revenue Growth
- VALU N/A
- CRVS N/A
- 52 Week Low
- VALU $36.00
- CRVS $1.30
- 52 Week High
- VALU $58.45
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- VALU 60.41
- CRVS 51.74
- Support Level
- VALU $49.43
- CRVS $8.67
- Resistance Level
- VALU $57.68
- CRVS $10.00
- Average True Range (ATR)
- VALU 1.97
- CRVS 0.84
- MACD
- VALU 0.32
- CRVS -0.18
- Stochastic Oscillator
- VALU 66.29
- CRVS 18.10
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under well-known brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and The Most Trusted Name in Investment Research. Its only operating segment being Publishing.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).